SLX-2101 – A PHOSPHODIESTERASE 5 INHIBITOR FOR CARDIOVASCULAR DISEASE
SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor designed specifically to expand
the therapeutic potential of PDE5 inhibition beyond erectile dysfunction into larger cardiovascular (CV) markets. The scientific
rationale for inhibiting PDE5 in cardiovascular tissue is compelling and includes (1) the induction of vasodilation through smooth
muscle relaxation and (2) the prevention and reversal of deleterious cardiac remodeling that results from sustained pressure
overload in hypertension.
|
Using its Pharmacomer™ Technology Platform, which selectively manipulates drug/protein and drug/tissue interactions,
Surface Logix has designed a PDE5 inhibitor that has enhanced cardiovascular tissue distribution, as determined by radiolabeled distribution
and volume of distribution (VD) analyses. This superior product profile allows for QD dosing with enhanced cardiovascular efficacy.
Clinical Development
Surface Logix has completed three Phase 1 clinical studies with SLx-2101, which established an excellent
initial profile in terms of safety, tolerability, dose response and efficacy. The company has also completed
four Phase 2a clinical studies in hypertension, Raynaud's disease and erectile dysfunction, all of which
demonstrated the efficacy of the compound in cardiovascular indications. Surface Logix is currently
progressing SLx-2101 in hypertension where it has demonstrated long acting, sustained reductions in
blood pressure.
|
|
